Glivec (that is imatinib mesylate) is a tyrosine kinase inhibitor previously approved by the FDA for treating CML and for treating patients with Kit (CD117) positive metastatic and/or unresectable malignant gastrointestinal stromal tumors (GIST). Here, KIT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.